Table 3.

Investigator-assessed antitumor activity of mobocertinib in patients with NSCLC with EGFRex20ins

5–40 mg/d80 mg total daily dosea120 mg/d160 mg/db
Efficacy endpoint(n = 12)(n = 9)(n = 21)(n = 28)
Best confirmed response, n (%)c
 Complete response01 (11)1 (5)0
 Partial response01 (11)3 (14)12 (43)
 Stable diseased3 (25)6 (67)11 (52)12 (43)
 Progressive disease7 (58)1 (11)3 (14)2 (7)
 Not evaluated2 (17)03 (14)2 (7)
Confirmed ORR, n (%) [95% CI]0 [0–26]2 (22) [3–60]4 (19) [5–42]12 (43) [24–63]
Confirmed disease control rate, n (%) [95% CI]3 (25) [5–57]8 (89) [52–100]15 (71) [48–89]24 (86) [67–96]
  • NOTE: Data cutoff: January 27, 2020.

  • aIncludes 80 mg/d and 40 mg twice daily.

  • bPatients treated with at least one dose of mobocertinib.

  • cBy RECIST version 1.1.

  • dStable disease observed ≥6 weeks after first study drug administration.